Clinical trials recruiting in Willowbrook, Illinois

Phase breakdown

Conditions recruiting in Willowbrook, Illinois

Recruiting trials in Willowbrook, Illinois

• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female)
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
  NCT07137598 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
  NCT06972446 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
  NCT07321873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
  NCT07430306 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
  NCT07276581 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
  NCT06991114 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
  NCT06133972 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female)
• Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
  NCT07404865 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
  NCT06865105 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
  NCT07621809 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Willowbrook, Illinois?

14 recruiting trials have at least one study site in Willowbrook, Illinois.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.